Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Gossamer Bio, Inc. (NASDAQ: GOSS). The investigation focuses on Gossamer’s executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Gossamer Bio securities?

If you purchased Gossamer Bio securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Click here to join the investigation.

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

Background of the investigation

On February 23, 2026, Gossamer Bio announced topline results from its Phase 3 PROSERA trial evaluating seralutinib for the treatment of pulmonary arterial hypertension (“PAH”). The Company reported a placebo-adjusted improvement in six-minute walk distance (“6MWD”) of +13.3 meters with a p-value of 0.0320.

Gossamer disclosed that the result did not meet the trial’s prespecified statistical significance threshold of α = 0.025. As a result, key secondary endpoints could not be formally evaluated for statistical significance.

Following this disclosure, Gossamer’s stock declined approximately 70% in pre-market trading, reflecting the market’s reaction to the failed primary endpoint.

In light of this disclosure, Johnson Fistel is investigating whether Gossamer Bio complied with the federal securities laws. If you suffered losses from your investment in Gossamer Bio stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights

Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.

Achievements

In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm’s effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs’ securities law firm in the United States, based on the total dollar value of final recoveries.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact

Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.